Amryt Pharma PLC said the U.S. Food and Drug Administration granted fast-track status to its investigational skin disease drug AP101.
![]() |
The company is developing AP101 as a potential treatment of epidermolysis bullosa, a group of diseases in which the skin gets easily injured, leading to painful blisters. There is currently no FDA-approved treatment for it.
London-based Amryt Pharma is a biopharmaceutical company engaged in developing new therapies for rare and orphan diseases.

